A detailed history of Neuberger Berman Group LLC transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 11,976 shares of ATRA stock, worth $92,334. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,976
Holding current value
$92,334
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$0.44 - $1.22 $5,269 - $14,610
11,976 New
11,976 $8,000
Q4 2023

Feb 09, 2024

BUY
$0.23 - $1.74 $2,561 - $19,378
11,137 New
11,137 $5,000
Q4 2019

Feb 12, 2020

SELL
$10.89 - $16.79 $10.6 Million - $16.4 Million
-977,925 Closed
0 $0
Q3 2019

Nov 13, 2019

SELL
$12.03 - $19.94 $4.67 Million - $7.74 Million
-388,091 Reduced 28.41%
977,925 $13.8 Million
Q2 2019

Aug 13, 2019

BUY
$19.05 - $41.04 $1.13 Million - $2.44 Million
59,365 Added 4.54%
1,366,016 $27.5 Million
Q1 2019

May 13, 2019

BUY
$28.4 - $41.74 $474,365 - $697,183
16,703 Added 1.29%
1,306,651 $51.9 Million
Q4 2018

Feb 12, 2019

BUY
$30.9 - $42.97 $2.21 Million - $3.07 Million
71,409 Added 5.86%
1,289,948 $44.8 Million
Q3 2018

Nov 13, 2018

BUY
$35.05 - $43.5 $2.62 Million - $3.26 Million
74,833 Added 6.54%
1,218,539 $50.4 Million
Q2 2018

Aug 13, 2018

BUY
$35.15 - $51.45 $1.73 Million - $2.53 Million
49,225 Added 4.5%
1,143,706 $42 Million
Q1 2018

May 08, 2018

BUY
$18.0 - $48.35 $1.48 Million - $3.98 Million
82,285 Added 8.13%
1,094,481 $42.7 Million
Q4 2017

Feb 14, 2018

SELL
$13.2 - $18.1 $1.36 Million - $1.86 Million
-102,845 Reduced 9.22%
1,012,196 $18.3 Million
Q3 2017

Nov 15, 2017

BUY
$13.25 - $17.05 $14.8 Million - $19 Million
1,115,041
1,115,041 $18.5 Million

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $728M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.